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Purpose or Objective  
Prostate cancer (Pca) patients can experience a 
significant decline in quality of life due to late toxicity 
after external beam radiotherapy (EBRT). Development 
of normal tissue complication probability (NTCP) models 
for late toxicity could predict the risk of toxicity after 
radiotherapy for Pca. The main purpose of this 
prospective cohort study was to develop comprehensive 
NTCP-profiles for Pca patients treated with radiotherapy. 
Material and Methods  
Dosimetric data of 302 Pca patients treated in the 
University Medical Center Groningen between 2006 and 
2010 were collected. Patient reported questionnaires 
were prospectively used to score toxicity according to the 
Radiation Therapy Oncology Group criteria. Baseline 
clinical data were retrospectively acquired from patient 
files; age, androgen deprivation therapy (ADT), 
acetylsalicylic acid tablets use, other anticoagulants 
agents use, pretreatment TURP and diabetic disease. All 
patients have been treated with EBRT to 78 Gy (39 
fractions of 2 Gy). The median follow-up was 60 months 
(range 4-120 months).  
The following toxicity symptoms were investigated in this 
model: rectal blood loss, fecal incontinence (requiring 
daily use of pads), obstipation (requiring daily use of 
laxatives) and abdominal cramping or pain. Multivariable 
logistic regression analysis was used to analyze dose 
volume effects and NTCP models were developed.  
Results  
The discriminating ability of the model was described by 
the area under the receiver operating characteristic 
curve (AUC). The discrimination slope was calculated as 
the absolute difference between the mean predicted 
NTCP value for patients with and without the outcome. 
Finally, the gain and intercept of the model calibration 
were calculated, and the calibration was evaluated using 
a Hosmer–Lemeshow test which was not significant in any 
of the models, indicating a good agreement between 
observed and expected outcomes. 
Rectal bleeding was significantly associated with V70 
rectal wall (volume of rectal wall receiving 70 Gy) 
[p=0.015; OR=1.081 (1.016-1.152)], anal canal V30 
(volume of anal canal receiving 30 Gy) [p=0.010; 
OR=1.022 (1.005-1.040)] and aspirin use [p=0.011; 
OR=3.215 (1.463-7.065)]. AUC=0.70 (0.60-0.79). Fecal 
incontinence was significantly associated with anal canal 
V10 (volume of anal canal receiving 10 Gy) [p=0.021; 
OR=1.040 (1.002-1.080)] and patient age [p=0.005; 
OR=1.140 (1.033-1.258)]. AUC=0.76 (0.65-0.87). Rectal 
pain was significantly associated with anorectum V70 
[p=0.007; OR=1.104 (1.028-1.186)] and ADT [p=0.049; 
OR=2.023 (1.002-4.084)]. AUC=0.67 (0.59-0.76). 
Conclusion  
We developed a comprehensive set of NTCP-models that 
can be used to predict the most relevant rectal toxicities 
in prostate cancer radiotherapy. The resulting NTCP-
profiles can be used for radiotherapy treatment dose 
optimization. In addition, these NTCP-profiles can be 
used in the future for model-based selection of patients 
for proton therapy, based on ∆NTCP-profiles.  
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